Potential Prognostic Markers for Glioblastoma Associated with the Glioma Immune Microenvironment

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• The glioma immune microenvironment (GIME) influences GBM progression and treatment response.
• Identifying prognostic markers within the GIME is crucial for developing effective therapies.

Purpose of the Study:

• To identify novel prognostic markers associated with the GIME in GBM.
• To explore the role of these markers in predicting GBM prognosis and immune responses.
• To evaluate potential biomarkers for guiding GBM immunotherapeutic strategies.

Main Methods:

• Integrated bioinformatics analysis of single-cell RNA-sequencing (scRNA-seq) and spatial transcriptome (ST) datasets from clinical GBM specimens.
• Identification of genes associated with poor prognosis across multiple GBM cohorts and subtypes.
• Correlation analysis with immune cell infiltration, immune gene expression, and ESTIMATEScore.
• scRNA-seq and ST analysis to pinpoint gene expression in specific cell types and tissue locations.

Main Results:

• 42 genes were identified as associated with poor GBM prognosis.
• 32 of these genes correlated positively with immune-related metrics.
• COLGALT1, ITGB2, and MYL12A were identified as key genes, with expression at the tumor-peritumoral interface.
• These genes showed enrichment in tumor-associated macrophages.

Conclusions:

• COLGALT1, ITGB2, and MYL12A show potential as biomarkers for predicting GBM prognosis.
• These markers may also predict immune responses in GBM patients.
• Findings support the development of novel immunotherapeutic strategies for GBM targeting these biomarkers.